Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Corcept Therapeutics Incorporated before investing.

In this article, we go over a few key elements for understanding Corcept Therapeutics Incorporated’s stock price such as:

• Corcept Therapeutics Incorporated’s current stock price and volume
• Why Corcept Therapeutics Incorporated’s stock price changed recently
• Upgrades and downgrades for CORT from analysts
• CORT’s stock price momentum as measured by its relative strength

About Corcept Therapeutics Incorporated (CORT)

Before we jump into Corcept Therapeutics Incorporated’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Want to learn more about Corcept Therapeutics Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated’s Stock Price as of Market Close

As of March 31, 2025, 4:00 PM, CST, Corcept Therapeutics Incorporated’s stock price was $114.220.

Corcept Therapeutics Incorporated is up 110.16% from its previous closing price of $54.350.

During the last market session, Corcept Therapeutics Incorporated’s stock traded between $87.582 and $117.330. Currently, there are approximately 103.64 million shares outstanding for Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated’s price-earnings (P/E) ratio is currently at 44.4, which is high compared to the Pharmaceuticals industry median of 18.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Corcept Therapeutics Incorporated Stock Price History

Corcept Therapeutics Incorporated’s (CORT) price is currently up 88.54% so far this month.

During the month of March, Corcept Therapeutics Incorporated’s stock price has reached a high of $117.330 and a low of $52.450.

Over the last year, Corcept Therapeutics Incorporated has hit prices as high as $75.000 and as low as $20.840. Year to date, Corcept Therapeutics Incorporated’s stock is up 126.67%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Corcept Therapeutics Incorporated Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 28, 2025, there were 4 analysts who downgraded Corcept Therapeutics Incorporated’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Corcept Therapeutics Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Corcept Therapeutics Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Corcept Therapeutics Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Corcept Therapeutics Incorporated (CORT) by visiting AAII Stock Evaluator.

Relative Price Strength of Corcept Therapeutics Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 28, 2025, Corcept Therapeutics Incorporated has a weighted four-quarter relative price strength of 17.72%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Corcept Therapeutics Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Corcept Therapeutics Incorporated Stock Price: Bottom Line

As of March 31, 2025, Corcept Therapeutics Incorporated’s stock price is $114.220, which is up 110.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Corcept Therapeutics Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.